Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

TALPHERA, INC. (TLPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a posi

Event · Earnings
Original reporting
Published Aug 12, 2026, 8:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$TLPH
Bullish
medium confidence
Mentioned
$TLPH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$TLPHBullishMed
01

Why it matters

The most tradable elements are (1) 75% enrollment with year-end completion expectation, (2) KDIGO 2026 guideline language citing nafamostat as an acceptable CRRT anticoagulant, and (3) updated U.S. CRRT procedure market estimate for 2027, plus (4) cash balance and operating loss trend.

02

Market read

This filing is a clinical progress and positioning update that can move sentiment ahead of the same-day investor call, but it lacks new clinical efficacy readouts.

03

What to watch

Cash is $17.1M at June 30, 2026 and expenses rose with enrollment, so dilution or additional financing risk could cap upside even if enrollment continues.

Relevance 7/10Novelty 6/10Timing: Aug 12, 2026 investor call at 4:30 pm ET

Background

The 8-K (Item 2.02) accompanies Talphera’s Q2 2026 financial results and a corporate update on its nafamostat program (Niyad) in the NEPHRO CRRT Phase 3 registrational study.

Company-level read

Ticker impact

$TLPHBullishMedium confidence
Context

Talphera reports Q2 2026 results and says NEPHRO CRRT enrollment is 75%, with KDIGO 2026 citing nafamostat as an acceptable CRRT anticoagulant.

Expected impact

Moderate upside bias into the Aug 12 investor call, with follow-through dependent on enrollment completion and subsequent regulatory/clinical milestones.

Evidence & confidence

The filing adds concrete progress (75% enrollment), a guideline update referencing nafamostat, and cash runway (cash and investments $17.1M). These are meaningful for a clinical-stage biotech, but there is no approval or new efficacy data disclosed here.

Market effects

Supports sentiment for CRRT anticoagulant development and for companies with nafamostat-based platforms, as guideline language can affect perceived adoption pathways.

Primarily US-focused given the stated U.S. CRRT procedure market sizing and Nasdaq compliance mention.

Limited direct global impact, though KDIGO guidance is international and may influence non-US clinical practice over time.

Counterpoint

Guideline inclusion does not guarantee trial success or approval; the article provides progress and positioning, not new Phase 3 efficacy or safety outcomes.

Key entities

  • Talphera, Inc.

    Nasdaq-listed specialty pharmaceutical company developing nafamostat (Niyad) for CRRT anticoagulation.

  • Nafamostat (Niyad)

    Lyophilized nafamostat formulation studied under IDE as an anticoagulant for the extracorporeal circuit.

  • NEPHRO CRRT study

    Prospective, double-blinded Phase 3 registrational trial targeting 70 adult patients; enrollment reported at 75%.

  • KDIGO 2026 Clinical Practice Guideline for AKI/AKD

    Guideline language cited in the release as referencing nafamostat as an acceptable regional anticoagulant during CRRT.

Related articles

$TLPHMed

Talphera (TLPH) Q3 2026 Earnings Call Transcript

Talphera (TLPH) reported Q3 2026 earnings, seeking FDA approval to conclude Niyad enrollment early due to 80% statistical power. They increased peak U.S. sales estimate to over $200M. Cash balance was $14.2M, with $16M in potential financing. Operating expenses rose to $3.8M from $3.3M YoY. Enrollment challenges were discussed, with no clear cause identified.

$TLPHMed

What Talphera (TLPH) Said on Its Q3 Earnings Call

Talphera (TLPH) discussed Q3 earnings, highlighting FDA submission details, increased peak-sales estimates, and cash position. The company expects $14.2M in cash and $16M in conditional financing to support operations through 2027. Expenses rose to $3.8M due to Niyad development and pre-launch activities. Talphera plans an investor event in Q1 2027 to discuss opportunities.

$TLPHMedAI 8/10

Talphera at H.C. Wainwright conference: nafamostat path gains traction

Talphera (TLPH) updated investors on its nafamostat mesylate clinical trial at the H.C. Wainwright conference. The NEPHRO study is 75% enrolled, with topline data expected in early 2025 and a potential U.S. launch in late 2025. The FDA reduced the study size to 70 patients, maintaining 90% statistical power. New guidelines recommend nafamostat, and the company sees a larger U.S. market opportunity. The stock has gained 56% over six months, with analysts setting price targets between $3 and $3.50